Skip to main content
Top
Published in: Internal and Emergency Medicine 5/2022

21-01-2022 | Colchicine | IM - ORIGINAL

Late-onset familial mediterranean fever: single-center experience and literature review

Authors: Okan Aydin, Bugra Han Egeli, Huri Ozdogan, Serdal Ugurlu

Published in: Internal and Emergency Medicine | Issue 5/2022

Login to get access

Abstract

Familial Mediterranean fever (FMF) is a hereditary, autoinflammatory disease characterized by recurrent fever and serositis attacks. The disease onset occurs before 20 years of age in 90% of patients and rarely after the 4th decade. The aim of this study is to screen our FMF patient pool for patients with disease onset after age of 40 and to compare them to patients with early onset with regard to clinical and genetic features. The charts of 2020 patients registered in our FMF center in the years 2008–2017 were screened with regard to age of disease onset. Patients with disease onset after the age of 40 were considered as late-onset group (Group 1). The control group (Group 2) consisted of patients with a disease onset before the age of 20 who were randomly selected from the patient pool with twice the number of probands. Demographic, clinical and genetic data were recorded. Out of 2020 patients, the attacks of FMF had started after the fourth decade in 41 patients (2.02%), (Group 1). The male to female ratio was 1:1.7 in both groups. The delay of diagnosis was 5.6 ± 5.75 years in group 1, 10.7 ± 12.3 years in group 2. The only significant difference with regard to clinical features between two groups was the frequency of fever, which was present in 26 (63.4%) patients in group 1 and 67 (81.7%) in group 2 (p = 0.026). M694V mutation was more prevalent among early-onset group whereas exon 2 variants were more frequent in patients with late onset. The mean colchicine dose in the last 6 months was 1.38 ± 0.64 mg in group 1, and 1.61 ± 0.47 mg in group 2. FMF may start after 40 years of age in approximately 2% of the patients. Lower frequency of fever, lower daily colchicine dose and lower prevalence of exon 10 mutations point out that FMF patients with a disease onset after 40 years of age experience a milder disease compared to those with an onset before the second decade of life.
Literature
1.
go back to reference Lidar M, Livneh A (2007) Familial Mediterranean fever: clinical, molecular and management advancements. Neth J Med 65(9):318–324PubMed Lidar M, Livneh A (2007) Familial Mediterranean fever: clinical, molecular and management advancements. Neth J Med 65(9):318–324PubMed
2.
go back to reference Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever A survey of 470 cases and review of the literature. Am J Med. 1967;43(2):227–53. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever A survey of 470 cases and review of the literature. Am J Med. 1967;43(2):227–53.
3.
4.
go back to reference Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G et al (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644–651CrossRef Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G et al (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644–651CrossRef
5.
go back to reference Egeli BH, Ugurlu S. Familial Mediterranean Fever: Clinical State Of The Art. QJM. 2020 Oct 20:hcaa291. Egeli BH, Ugurlu S. Familial Mediterranean Fever: Clinical State Of The Art. QJM. 2020 Oct 20:hcaa291.
6.
go back to reference Wilson SP, Cassel SL (2010) Inflammasome-mediated autoinflammatory disorders. Postgrad Med 122(5):125–133CrossRef Wilson SP, Cassel SL (2010) Inflammasome-mediated autoinflammatory disorders. Postgrad Med 122(5):125–133CrossRef
7.
go back to reference Touitou I (2001) The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet 9(7):473–483CrossRef Touitou I (2001) The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet 9(7):473–483CrossRef
8.
go back to reference Ben-Chetrit E, Levy M (1998) Familial Mediterranean fever. Lancet (London, England) 351(9103):659–664CrossRef Ben-Chetrit E, Levy M (1998) Familial Mediterranean fever. Lancet (London, England) 351(9103):659–664CrossRef
9.
go back to reference Federici S, Sormani MP, Ozen S, Lachmann HJ, Amaryan G, Woo P, et al. Paediatric Rheumatology International Trials Organisation (PRINTO) and Eurofever Project. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis. 2015;74(5):799–805. Federici S, Sormani MP, Ozen S, Lachmann HJ, Amaryan G, Woo P, et al. Paediatric Rheumatology International Trials Organisation (PRINTO) and Eurofever Project. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis. 2015;74(5):799–805.
10.
go back to reference Sayarlioglu M, Cefle A, Inanc M, Kamali S, Dalkilic E, Gul A et al (2005) Characteristics of patients with adult-onset familial Mediterranean fever in Turkey: analysis of 401 cases. Int J Clin Pract 59(2):202–205CrossRef Sayarlioglu M, Cefle A, Inanc M, Kamali S, Dalkilic E, Gul A et al (2005) Characteristics of patients with adult-onset familial Mediterranean fever in Turkey: analysis of 401 cases. Int J Clin Pract 59(2):202–205CrossRef
11.
go back to reference Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885CrossRef Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885CrossRef
12.
go back to reference Endo Y, Koga T, Ishida M, Fujita Y, Tsuji S, Takatani A et al (2018) Musculoskeletal manifestations occur predominantly in patients with later-onset familial Mediterranean fever: data from a multicenter, prospective national cohort study in Japan. Arthritis Res Ther 20(1):257CrossRef Endo Y, Koga T, Ishida M, Fujita Y, Tsuji S, Takatani A et al (2018) Musculoskeletal manifestations occur predominantly in patients with later-onset familial Mediterranean fever: data from a multicenter, prospective national cohort study in Japan. Arthritis Res Ther 20(1):257CrossRef
13.
go back to reference Kishida D, Yazaki M, Nakamura A, Tsuchiya-Suzuki A, Shimojima Y, Sekijima Y. Late-onset familial Mediterranean fever in Japan. Mod Rheumatol. 2019:1–4 Kishida D, Yazaki M, Nakamura A, Tsuchiya-Suzuki A, Shimojima Y, Sekijima Y. Late-onset familial Mediterranean fever in Japan. Mod Rheumatol. 2019:1–4
14.
go back to reference Ureten K, Gönülalan G, Akbal E, Güneş F, Akyürek O, Ozbek M, Oztürk MA (2010) Demographic, clinical and mutational characteristics of Turkish familial Mediterranean fever patients: results of a single center in Central Anatolia. Rheumatol Int 30(7):911–915CrossRef Ureten K, Gönülalan G, Akbal E, Güneş F, Akyürek O, Ozbek M, Oztürk MA (2010) Demographic, clinical and mutational characteristics of Turkish familial Mediterranean fever patients: results of a single center in Central Anatolia. Rheumatol Int 30(7):911–915CrossRef
15.
go back to reference Tamir N, Langevitz P, Zemer D, Pras E, Shinar Y, Padeh S et al (1999) Late-onset familial Mediterranean fever (FMF): a subset with distinct clinical, demographic, and molecular genetic characteristics. Am J Med Genet 87(1):30–35CrossRef Tamir N, Langevitz P, Zemer D, Pras E, Shinar Y, Padeh S et al (1999) Late-onset familial Mediterranean fever (FMF): a subset with distinct clinical, demographic, and molecular genetic characteristics. Am J Med Genet 87(1):30–35CrossRef
16.
go back to reference Kriegshäuser G, Enko D, Hayrapetyan H, Atoyan S, Oberkanins C, Sarkisian T (2018) Clinical and genetic heterogeneity in a large cohort of Armenian patients with late-onset familial Mediterranean fever. Genet Med 20(12):1583–1588CrossRef Kriegshäuser G, Enko D, Hayrapetyan H, Atoyan S, Oberkanins C, Sarkisian T (2018) Clinical and genetic heterogeneity in a large cohort of Armenian patients with late-onset familial Mediterranean fever. Genet Med 20(12):1583–1588CrossRef
17.
go back to reference Kasifoglu T, Bilge SY, Sari I, Solmaz D, Senel S, Emmungil H et al (2014) Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study. Rheumatology (Oxford) 53(4):741–745CrossRef Kasifoglu T, Bilge SY, Sari I, Solmaz D, Senel S, Emmungil H et al (2014) Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study. Rheumatology (Oxford) 53(4):741–745CrossRef
18.
go back to reference Yasar Bilge NS, Sari I, Solmaz D, Senel S, Emmungil H, Kilic L et al (2018) Comparison of early versus late onset familial Mediterranean fever. Int J Rheum Dis 21(4):880–884CrossRef Yasar Bilge NS, Sari I, Solmaz D, Senel S, Emmungil H, Kilic L et al (2018) Comparison of early versus late onset familial Mediterranean fever. Int J Rheum Dis 21(4):880–884CrossRef
19.
go back to reference Tirosh I, Yacobi Y, Vivante A, Barel O, Ben-Moshe Y, Erez Granat O, et al. Clinical significance of E148Q heterozygous variant in paediatric Familial Mediterranean Fever. Rheumatology (Oxford). 2021 Feb 9:keab128. Tirosh I, Yacobi Y, Vivante A, Barel O, Ben-Moshe Y, Erez Granat O, et al. Clinical significance of E148Q heterozygous variant in paediatric Familial Mediterranean Fever. Rheumatology (Oxford). 2021 Feb 9:keab128.
20.
go back to reference Atoyan S, Hayrapetyan H, Yeghiazaryan A, Ben-Chetrit E, Sarkisian T (2020) Is the country of living important in the phenotypic expression of E148Q mutation? The Armenian experience. Clin Exp Rheumatol 38(Suppl 127):124–125PubMed Atoyan S, Hayrapetyan H, Yeghiazaryan A, Ben-Chetrit E, Sarkisian T (2020) Is the country of living important in the phenotypic expression of E148Q mutation? The Armenian experience. Clin Exp Rheumatol 38(Suppl 127):124–125PubMed
21.
go back to reference Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F, et al. Turkish FMF Study Group. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84(1):1–11. Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F, et al. Turkish FMF Study Group. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84(1):1–11.
Metadata
Title
Late-onset familial mediterranean fever: single-center experience and literature review
Authors
Okan Aydin
Bugra Han Egeli
Huri Ozdogan
Serdal Ugurlu
Publication date
21-01-2022
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 5/2022
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-021-02912-8

Other articles of this Issue 5/2022

Internal and Emergency Medicine 5/2022 Go to the issue